Patents Assigned to Université Libre de Bruxelles
  • BETA CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS
    Publication number: 20140005220
    Abstract: The invention provides novel beta-carboline derivatives of formulae (Ia) and (Ib) useful in the treatment of proliferative disorders including cancer, intermediates used in their preparation, processes for preparing the same and uses thereof.
    Type: Application
    Filed: June 24, 2011
    Publication date: January 2, 2014
    Applicants: UNIVERSITE LIBRE DE BRUXELLES, FACULTES UNIVERSITAIRES NOTRE DAME DE LA PAIX
    Inventors: Raphael Frederick, Bernard Masereel, Jeremy Reniers, Johan Wouters, Celine Bruyere, Robert Kiss
  • METHOD FOR DETERMINING SUSPENDED MATTER LOADS CONCENTRATIONS IN A LIQUID
    Publication number: 20130338937
    Abstract: The present invention relates to a method for monitoring suspended matter loads concentration in a liquid, wherein said method comprises the steps of: a) collecting environmental variables comprising: the pressure p at a depth L in said liquid, the liquid depth L at which said pressure p is collected; providing the value of the pressure p0 which is the aerial pressure; b) inserting said environmental variables in an equation; c) calculating the suspended matter loads volumetric concentration in the liquid from the absolute pressure p measured at the depth L in the liquid.
    Type: Application
    Filed: March 9, 2012
    Publication date: December 19, 2013
    Applicant: UNIVERSITE LIBRE DE BRUXELLES
    Inventors: Michel Verbanck, Dragana Petrovic, Jean-Pierre Vanderborght
  • BACH2 REPRESSION IN CELLS
    Publication number: 20130338023
    Abstract: A method for measuring the proliferation status of a cell present in a biological sample, comprising the step of measuring in the said cell the loss of BACH2 by Fluorescence after In Situ Hybridization (FISH) analysis and mRNA quantification or by Comparative Genomic Hybridization (CGH) and corresponding kit and applications.
    Type: Application
    Filed: October 12, 2011
    Publication date: December 19, 2013
    Applicant: UNIVERSITE LIBRE DE BRUXELLES
    Inventors: Karen Willard-Gallo, Catherine Sibille
  • Method and kit for the detection of genes associated with PIK3CA mutation and involved in PI3K/AKT pathway activation in the ER-postitive and HER2-positive subtypes with clinical implications
    Patent number: 8580496
    Abstract: A method to determine the clinical outcome of breast tumor affecting a patient if treated with an antitumoral agent against breast tumor. The method includes the step of assaying a sample of a breast tumor from the patient for an expression level of selected genes, by contacting mRNA sequences from the cells of this breast tumor with a set of more than 3 nucleotide sequences related to human mutated PIK3CA.
    Type: Grant
    Filed: August 20, 2010
    Date of Patent: November 12, 2013
    Assignee: Universite Libre de Bruxelles
    Inventors: Christos Sotiriou, Sherene Loi, Grant McArthur, Benjamin Haibe-Kains
  • EPIGENETIC PORTRAITS OF HUMAN BREAST CANCERS
    Publication number: 20130296328
    Abstract: The present invention provides new target gene regions for use in prediction, prognosis, diagnosis and therapy of breast cancer, based on the differential methylation profile of said targets in samples from subjects with breast cancer and healthy subjects.
    Type: Application
    Filed: January 20, 2012
    Publication date: November 7, 2013
    Applicant: Université Libre de Bruxelles
    Inventors: François Fuks, Sarah Dedeurwaerder, Christos Sotiriou, Christine Desmedt
  • NOVEL PHENAZINE DERIVATIVES AND THEIR USES
    Publication number: 20130289030
    Abstract: The present invention is directed to novel compounds of formula I and their use as anti-angiogenic agents and anti-cancer agents.
    Type: Application
    Filed: December 22, 2011
    Publication date: October 31, 2013
    Applicants: UNIVERSITE LIBRE DE BRUXELLES, UNIVERSITE CATHOLIQUE DE LOUVAIN
    Inventors: Olivier Feron, Olivier Riant, Robert Kiss, Joelle Leclercq, Gabrielle Chataigne, Nicolas Vandelaer, Carole Lamy
  • Recombinant alpha-hemolysin polypeptide of , having a deletion in the stem domain and heterologous sequences inserted
    Patent number: 8545853
    Abstract: It refers to a recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, comprising a deletion in the stem domain, wherein at least one heterologous sequence is inserted in a region selected from the group consisting of regions defined by amino acid position of 108 to 151, 1 to 5, 288 to 293, 43 to 48, 235 to 240, 92 to 97, 31 to 36,or 156 to 161 of SEQ ID NO: 1, with the proviso that, if the heterologous sequence contains five or more consecutive histidines the moiety of the heterologous sequence other than the moiety of five or more consecutive histidines has a minimum length of 11 amino acids; or a variant thereof comprising 1-50 amino acids added, substituted or deleted in SEQ ID NO. 1 and the activity to form oligomers and to bind to lipidic bilayers. It also provides a medicament and vaccine comprising said recombinant polypeptide.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: October 1, 2013
    Assignees: Universite de Liege, Centre d'Economie Rurale, Universite Libre de Bruxelles
    Inventors: Patrice Filee, Noureddine Rhazi, Moreno Galleni, Bernard Taminiau, Olivier Jolois, Alfred Collard, Alain Jacquet
  • Method for the selection of recombination clones comprising a sequence encoding an antidote protein to a toxic molecule
    Patent number: 8470580
    Abstract: The present invention is related to a method for the selection of recombinant clones having integrated a gene of interest and a nucleotide sequence encoding a functional antidote protein to a toxic molecule, wherein said recombinant clones are the ones which survive following their integration into a host cell comprising in its genome a nucleotide sequence encoding said toxic molecule. The present invention is also related to a nucleic acid construct, a vector comprising said nucleic acid construct, a host cell and a cloning and/or sequencing kit for performing said method.
    Type: Grant
    Filed: February 22, 2002
    Date of Patent: June 25, 2013
    Assignee: Universite Libre de Bruxelles
    Inventors: Philippe Gabant, Laurence Van Melderen, Cédric Yves Szpirer
  • BETA CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS
    Publication number: 20130116273
    Abstract: The invention provides novel beta-carboline derivatives of formulae (Ia) and (Ib) useful in the treatment of proliferative disorders including cancer, intermediates used in their preparation, processes for preparing the same and uses thereof.
    Type: Application
    Filed: June 24, 2011
    Publication date: May 9, 2013
    Applicants: UNIVERSITE LIBRE DE BRUXELLES, FACULTES UNIVERSITAIRES NOTRE DAME DE LA PAIX
    Inventors: Raphael Frederick, Bernard Masereel, Jeremy Reniers, Johan Wouters, Celine Bruyere, Robert Kiss
  • HYPERPROLIFERATIVE RECOMBINANT CELL
    Publication number: 20130109061
    Abstract: A method increases the growth of a cell by a deletion or one or more mutation(s) in the tldD and/or tldE genes, coupled with one or more mutation(s) in dam or a partial deletion or deletion of the dam gene. A cell is obtained by the method and used.
    Type: Application
    Filed: May 20, 2011
    Publication date: May 2, 2013
    Applicant: UNIVERSITE LIBRE DE BRUXELLES
    Inventors: Laurence Van Melderen, Johan Timmermans
  • Plasma membrane biomarkers preferentially expressed in pancreatic beta cells useful in imaging or targeting beta cells
    Patent number: 8425878
    Abstract: The present invention is directed to the identification of a biomarker specifically located in the plasma membrane of pancreatic beta cells. It was selected by a Systems Biology approach on Massively Parallel Signal Sequencing datasets obtained in human islets and Affymetrix microarray datasets on human islets, purified rat primary beta and non beta cells and insulinoma cells. Based on a set of specific features the biomarker is a unique candidate for imaging and targeting strategies to study the pancreatic beta cell mass in health and disease (T1 D, T2D, pancreatic cancers, obesity, islet transplantation, beta cell regeneration).
    Type: Grant
    Filed: February 13, 2009
    Date of Patent: April 23, 2013
    Assignee: Universite Libre de Bruxelles
    Inventors: Decio L. Eizirik, Daisy Flamez, Isabelle Salmon, Alix Berton, Isabelle Roland, Daniel Marechal, Marie-Claire Beckers, Leroy Hood, Nathan Goodman, Burak Kutlu
  • Method for evaluating the response of an individual to a treatment with a type I interferon (IFN)
    Patent number: 8426170
    Abstract: A method for evaluating the in vivo presence of a factor that prevents the biological effect of a type I (IFN) in an individual that is under treatment with type I interferon is described. The in vivo presence of antibodies directed against a type I interferon (IFN) is evaluated in an individual that is under treatment with type I interferon. The method includes incubating a blood sample of the individual in vitro with a suitable amount of the type I interferon for a suitable period of time, and determining mRNA levels of a biological marker of IFN activity, preferably MxA, in the blood sample. The treatment may involve a treatment of multiple sclerosis, HCV or HBV using a type I interferon.
    Type: Grant
    Filed: January 24, 2008
    Date of Patent: April 23, 2013
    Assignee: Universite Libre de Bruxelles
    Inventors: Patrick Stordeur, Mathieu Vokaer, Annick Ocmant, Michel Goldman
  • PRO-DRUGS OF AMARYLLIDACEAE ISOCARBOSTYRIL PRODUCTS AND THEIR USE AGAINST BRAIN TUMORS
    Publication number: 20130053347
    Abstract: The present invention relates to the biology and mechanism of action of the naturally occurring compound Narciclasine, especially as an anti-cancer agent for brain tumors. The invention provides new insights on the target molecule of Amaryllidaceae isocarbostyril derivatives as for example Narciclasine and provides new prodrugs of these Amaryllidceae isocabostyril constituents for treating cancer, specifically cancers or tumors located in the brain.
    Type: Application
    Filed: May 3, 2010
    Publication date: February 28, 2013
    Applicant: Universite Libre de Bruxelles
    Inventors: Veronique Mathieu, Gwendoline Van Goietsenoven, Jacques Dubois, Florence Lefranc-Kiss, Laurent Ingrassia, Robert Kiss
  • Leukotriene B4 binding soluble lipocalin receptor from ixodes ricinus
    Patent number: 8324161
    Abstract: Leukotriene B4 binding polypeptide is obtained from Ixodes ricinus. Leukotriene B4 polypeptide, the polynucleotide encoding Leukotriene B4 polypeptide, and Leukotriene B4 polypeptide related polypeptides may be used as research reagents and for treatments and diagnostics specific to animal and human diseases.
    Type: Grant
    Filed: September 10, 2008
    Date of Patent: December 4, 2012
    Assignees: Universite Libre de Bruxelles, Faculte Universitaire des Sciences Agronomiques de Gembloux
    Inventors: Edmond Godfroid, Jérôme Beaufays, Luc Vanhamme, Benoît Adam, Laurence Lins, Sébastien Santini, Robert Brasseur
  • TOOLS FOR ISOLATING AND FOLLOWING CARDIOVASCULAR PROGENITOR CELLS
    Publication number: 20120301445
    Abstract: The present invention provides new methods and tools for isolating pluripotent cardiovascular progenitors (MCPs), by transiently detecting the cell-surface expression of genes upregulated by Mesp1. Cells obtained by the method and there uses in research and clinical settings are also part of the invention. Using genome wide transcriptional analysis, the inventors found upstream and downstream members of the Mesp1 signaling pathway, which form potential new targets for both therapy and for the identification of MCPs and differentiation of MCPs into cardiovascular cells. This invention provides novel and important insights into the molecular mechanisms of cardiovascular specification and provides potential novel methods for dramatically increasing the number of cardiovascular cells for cellular therapy in humans.
    Type: Application
    Filed: December 31, 2010
    Publication date: November 29, 2012
    Applicant: Universite Libre de Bruxelles
    Inventors: Cedric Blanpain, Antoine Bondue
  • Reversible, parallel and multitask cloning method and kit
    Patent number: 8318497
    Abstract: The present invention is related to a reversible, parallel and/or multitask cloning method and kit, which improve the cloning of (preferably multiple) genetic element(s) in a nucleic acid construct such as vector or in chromosome of a cell and the rapid and efficient selection of said construct with a correct integration of said genetic element(s) either in vitro or in vivo.
    Type: Grant
    Filed: September 3, 2003
    Date of Patent: November 27, 2012
    Assignee: Universite Libre de Bruxelles
    Inventors: Cédric Szpirer, Michel C. Milinkovitch, Philippe Gabant
  • NETWORK DISTRIBUTED QUANTUM RANDOM NUMBER GENERATION
    Publication number: 20120221615
    Abstract: A quantum random number generation system includes a source of light output as a plurality of coherent states such that each state has an indeterminate number of photons, a photodetector arranged to receive the light output from the light source and to generate a photocurrent dependent on the number of photons in each coherent state, and processing circuitry connected to receive the photocurrent and arranged to convert it to generate a sequence of random numbers.
    Type: Application
    Filed: February 24, 2012
    Publication date: August 30, 2012
    Applicant: UNIVERSITE LIBRE DE BRUXELLES
    Inventors: Nicolas Cerf, Louis-Philippe Lamoureux, Julien Niset
  • SODA-LIME-SILICA GLASS-CERAMIC MATERIAL
    Publication number: 20120202676
    Abstract: The invention relates to a glass-ceramic material having SiO2, Na2O and CaO as main components and comprising crystalline particles of SiO2 dispersed homogeneously in the volume of an amorphous matrix. Such a material has good mechanical strength, in particular good resistance to scratch propagation and allows improved tempering. This material furthermore has a pleasant aesthetic appearance.
    Type: Application
    Filed: October 26, 2010
    Publication date: August 9, 2012
    Applicants: Universite Libre de Bruxelles, AGC GLASS EUROPE
    Inventors: Michel Bogaerts, Stephane Godet
  • PHASE-SEPARATED SODA-LIME-SILICA GLASS
    Publication number: 20120196735
    Abstract: The invention relates to a glass having SiO2, Na2O and CaO as main components, which comprises two amorphous phases having different compositions, one of the two phases being in the form of inclusions dispersed in the volume of the other phase and comprising crystalline particles. Such a glass has good mechanical strength, in particular good resistance to scratch propagation and allows improved tempering. This glass furthermore has a pleasant aesthetic appearance.
    Type: Application
    Filed: October 26, 2010
    Publication date: August 2, 2012
    Applicants: UNIVERSITE LIBRE DE BRUXELLES, AGC GLASS EUROPE
    Inventors: Michel Bogaerts, Stephane Godet
  • MARKER FOR DIAGNOSIS OF ACTIVE MULTIPLE SCLEROSIS
    Publication number: 20120190031
    Abstract: The invention provides an improved method for monitoring the course of the MS disease and to predict, diagnose or prognosticate whether a subject is in an active or non-active period of MS. The method is based on determining the ratio of the expression levels of two cytokines, measured before and after stimulation of the subject by an immunomodulator.
    Type: Application
    Filed: March 25, 2010
    Publication date: July 26, 2012
    Applicant: UNIVERSITÉ LIBRE DE BRUXELLES
    Inventors: Patrick Stordeur, Françoise Villée, Mathieu Vokaer, Annick Ocmant, Michel Goldman